Performance supplements

HMB

A leucine metabolite with inconsistent training results; large gains from one trial should not be treated as a dependable forecast.

Randomized training studies with discordant results

Practical use

Applying the explained evidence

Where it fits: A leucine metabolite with inconsistent training results; large gains from one trial should not be treated as a dependable forecast.
Put the information into practice: Comparator quality matters: HMB versus placebo asks a different question from HMB versus leucine when both groups already receive whey protein.
Connect evidence to your training: Specify the outcome you want to improve and a repeatable way to measure it. Check whether the study participants, activity and product match the claim; avoid crediting one supplement for changes made alongside several training or diet changes.
Keep this limit in view: It is a single intervention result with a specific program and comparator, not a personal forecast.

Twelve-week free-acid trial

Whey plus HMB versus whey plus leucine

Overview

HMB is beta-hydroxy-beta-methylbutyrate, a leucine metabolite. Calcium-salt and free-acid preparations have both been studied. Mechanistic claims about protein turnover require confirmation with actual muscle and strength outcomes.

Risks and limitations

The cited small training trials cannot rule out uncommon adverse effects or establish years-long safety. Favorable creatine-kinase changes are not proof that all tissue damage or drug-related risk has been prevented.

How to read this

Comparator quality matters: HMB versus placebo asks a different question from HMB versus leucine when both groups already receive whey protein.

Research explained

Large reported gains in one study

Who was studied

Resistance-trained participants; 12-week randomized training program including overreaching and taper.

Reported lean-mass gain: HMB: 7.4 kg
Reported lean-mass gain: placebo: 2.1 kg

What was found

Lean mass increased 7.4 kg in the free-acid HMB arm versus 2.1 kg with placebo; combined strength rose 77.1 versus 25.3 kg.

What it cannot establish

These unusually large study-specific results require independent replication; lean mass is not identical to newly grown contractile muscle. The accessed abstract omits group sample sizes.

Read the original study

No advantage over leucine with whey

Who was studied

26 resistance-trained young men; 12-week randomized comparison with overreaching and taper.

What was found

Both groups improved body composition, muscle measurements and strength, with no significant group differences at any phase.

What it cannot establish

Active comparator and calcium formulation differ from the free-acid placebo study. Absence of superiority does not prove exact equivalence in every setting.

Read the original study

Read the comparator before ranking

The later experiment compared two additions to whey, not HMB against no supplemental protein.

Supporting source

Lean mass is broader than muscle protein

A body-composition estimate contains multiple nonfat tissues and water. Reported lean kilograms should not be presented as pure permanent muscle.

Supporting source

A recovery marker is not a safety shield

The free-acid trial measured creatine kinase and performance during overreaching, not protection against cardiovascular or endocrine drug harms.

Supporting source

Correction transparency

The later comparison has a published corrigendum adding an investigator’s patent, equity and outside-fee disclosures. It does not correct the reported numerical outcomes.

Supporting source